Stock A241820 PCL, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials PCL, Inc.

Equities

A241820

KR7241820000

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
1,201 KRW -0.25% Intraday chart for PCL, Inc. -1.40% -66.50%
Jan. 16 PCL, Inc. announced that it has received KRW 9.99999885 billion in funding from Global Emerging Markets CI
2023 PCL, Inc. announced that it has received KRW 9.99999838 billion in funding from Global Emerging Markets CI

Valuation

Fiscal Period: December 2020 2021 2022 2023
Capitalization 1 368,384 365,077 175,405 184,730
Enterprise Value (EV) 1 367,580 356,895 174,119 191,935
P/E ratio 18.6 x -11.4 x -39.2 x -7.17 x
Yield - - - -
Capitalization / Revenue 6.86 x 7.91 x 4.71 x 21.9 x
EV / Revenue 6.85 x 7.73 x 4.68 x 22.8 x
EV / EBITDA 13.6 x -15 x -30.5 x -14.2 x
EV / FCF - 41,355,296 x -12,271,456 x -8,117,405 x
FCF Yield - 0% -0% -0%
Price to Book 10 x 25.3 x 5.66 x 5.2 x
Nbr of stocks (in thousands) 30,237 30,808 35,198 51,529
Reference price 2 12,183 11,850 4,983 3,585
Announcement Date 3/30/22 3/30/22 3/23/23 3/20/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023
Net sales 1 53,683 46,148 37,217 8,430
EBITDA 1 27,027 -23,734 -5,717 -13,505
EBIT 1 25,676 -25,766 -8,303 -16,370
Operating Margin 47.83% -55.83% -22.31% -194.2%
Earnings before Tax (EBT) 1 19,509 -31,672 -4,011 -20,365
Net income 1 19,509 -31,669 -4,018 -20,318
Net margin 36.34% -68.63% -10.79% -241.03%
EPS 2 655.8 -1,043 -127.1 -500.3
Free Cash Flow - 8,630 -14,189 -23,645
FCF margin - 18.7% -38.12% -280.5%
FCF Conversion (EBITDA) - - - -
FCF Conversion (Net income) - - - -
Dividend per Share - - - -
Announcement Date 3/30/22 3/30/22 3/23/23 3/20/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023
Net Debt 1 - - - 7,204
Net Cash position 1 804 8,182 1,285 -
Leverage (Debt/EBITDA) - - - -0.5334 x
Free Cash Flow - 8,630 -14,189 -23,645
ROE (net income / shareholders' equity) - -111% -14.8% -56.9%
ROA (Net income/ Total Assets) - -26.2% -6.21% -13.6%
Assets 1 - 120,801 64,733 149,069
Book Value Per Share 2 1,215 468.0 880.0 689.0
Cash Flow per Share 2 138.0 1,229 728.0 136.0
Capex 1 2,829 6,602 2,770 3,259
Capex / Sales 5.27% 14.31% 7.44% 38.66%
Announcement Date 3/30/22 3/30/22 3/23/23 3/20/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Diagnostics & Testing

1st Jan change Capi.
PCL, INC. Stock PCL, Inc.
-66.50% 47.15M
EXACT SCIENCES CORPORATION Stock Exact Sciences Corporation
-20.45% 10.82B
IOVANCE BIOTHERAPEUTICS, INC. Stock Iovance Biotherapeutics, Inc.
+43.17% 3.25B
GUARDANT HEALTH, INC. Stock Guardant Health, Inc.
-35.86% 2.11B
BGI GENOMICS CO., LTD. Stock BGI Genomics Co., Ltd.
-17.21% 2.08B
VERACYTE, INC. Stock Veracyte, Inc.
-29.81% 1.48B
MARAVAI LIFESCIENCES HOLDINGS, INC. Stock Maravai LifeSciences Holdings, Inc.
+17.56% 1.02B
SEEGENE, INC. Stock Seegene, Inc.
-4.37% 733M
CAREDX, INC Stock CareDx, Inc
-37.00% 391M
ADAPTIVE BIOTECHNOLOGIES CORPORATION Stock Adaptive Biotechnologies Corporation
-46.94% 377M
Bio Diagnostics & Testing
  1. Stock Market
  2. Equities
  3. A241820 Stock
  4. Financials PCL, Inc.